BioSpace News Archive

Veracyte, Inc. announced financial results for the first quarter ended March 31, 2023.

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced financial results for the first quarter and provided a business update.

Stoke Therapeutics, Inc. today reported financial results for the first quarter of 2023 and provided business updates including those related to STK-001, the company’s proprietary antisense oligonucleotide (ASO) being developed by Stoke as the first potential new medicine to address the genetic cause of Dravet syndrome.

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its first quarter 2023 results and recent business performance.

AlloVir today reported financial results from the first quarter ended March 31, 2023.

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2023.

Henry Schein, Inc. announced an agreement to acquire S.I.N. Implant System, one of Brazil’s leading manufacturers of dental implants, pending regulatory approval.

Bausch Health Companies Inc. today announced its first-quarter 2023 financial results.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results for the first quarter 2023, recent business highlights, and upcoming milestones.

Theratechnologies Inc. today presented data from a landmark study in which the use of ibalizumab, a monoclonal antibody antiretroviral therapy (ART) commercialized as Trogarzo®, was associated with favorable virologic outcomes compared to non-ibalizumab regimens used in routine care in heavily treatment-experienced people with HIV.